Subtype
Malignant Exocrine Pancreas Neoplasm
CI-CAN-00003152Explore in graph →
360 active trials5 approved drugs27 evidence items
Loading cancer entity…
Subtype
CI-CAN-00003152Explore in graph →
Clinical trials
930 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (136)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01971281 | Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA) | unknown | Phase 1 / Phase 2 | 40 | NovoCure Ltd.INDUSTRY | 2 | Sep 13, 2017 | clinicaltrials |
| NCT01783171 | Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 2 | Aug 22, 2017 |
| clinicaltrials |
| NCT00288093 | 3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2017 | clinicaltrials |
| NCT01764477 | Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma | completed | Phase 1 | 20 | Prism Pharma Co., Ltd.INDUSTRY | 1 | Aug 17, 2017 | clinicaltrials |
| NCT03251365 | Intrabdominal Hyperthermic Chemotherapy and Pancreatic Cancer | unknown | Phase 2 / Phase 3 | 42 | Hospital General de Ciudad RealOTHER | 1 | Aug 16, 2017 | clinicaltrials |
| NCT03202199 | Neoadjuvant Chemotherapy Response Assessment by Combined PET-MRI in Borderline and Locally Advanced Pancreatic Adenocarcinoma.(PACMI) | unknown | N/A | 125 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 26, 2017 | clinicaltrials |
| NCT01729481 | Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer(ML22774) | unknown | Phase 2 | 150 | Ludwig-Maximilians - University of MunichOTHER | 1 | Jul 19, 2017 | clinicaltrials |
| NCT00609336 | Perioperative Therapy for Resectable Pancreatic Cancer | completed | Phase 2 | 35 | University of WashingtonOTHER | 1 | Jul 13, 2017 | clinicaltrials |
| NCT01016483 | Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer | completed | Phase 1 / Phase 2 | 141 | EMD SeronoINDUSTRY | 2 | Jul 13, 2017 | clinicaltrials |
| NCT02117258 | Z-360 Plus GEM in Subjects With Metastatic Pancreatic Adenocarcinoma(ZIPANG) | completed | Phase 2 | 167 | Zeria PharmaceuticalINDUSTRY | 3 | Jul 2, 2017 | clinicaltrials |
| NCT00366457 | Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer | completed | Phase 2 | 32 | Massachusetts General HospitalOTHER | 1 | May 15, 2017 | clinicaltrials |
| NCT02202785 | A Study of MLN0264 in Patients With Pancreatic Cancer | terminated | Phase 2 | 43 | Millennium Pharmaceuticals, Inc.INDUSTRY | 4 | May 15, 2017 | clinicaltrials |
| NCT00948688 | Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas | terminated | Phase 1 / Phase 2 | 10 | Massachusetts General HospitalOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT02567396 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Apr 24, 2017 | clinicaltrials |
| NCT02174887 | Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer(MOAnab1) | completed | Phase 1 | 19 | Institut Paoli-CalmettesOTHER | 1 | Mar 28, 2017 | clinicaltrials |
| NCT01753479 | Spectroscopy From Duodenum | completed | N/A | 445 | Olympus CorporationINDUSTRY | 3 | Mar 7, 2017 | clinicaltrials |
| NCT02685553 | Near Infrared Technology and Laparoscopic Resection of Pancreatic Lesions: the COLPAN Project | completed | Phase 1 | 10 | Universita di VeronaOTHER | 1 | Mar 7, 2017 | clinicaltrials |
| NCT03063554 | EUS BD vs ERCP TP for Pancreatic Cancer(BILPAL) | unknown | N/A | 120 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 24, 2017 | clinicaltrials |
| NCT01369420 | NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pancreatic Cancer | completed | Phase 2 | 10 | Angiodynamics, Inc.INDUSTRY | 1 | Nov 8, 2016 | clinicaltrials |
| NCT02607826 | Short-term Starvation vs. Normal Diet Before Chemotherapy of Solid Tumors | unknown | N/A | 298 | University Hospital TuebingenOTHER | 0 | Oct 28, 2016 | clinicaltrials |
| NCT02929797 | Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer(AKT) | unknown | Early Phase 1 | 72 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 11, 2016 | clinicaltrials |
| NCT01360853 | Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer(ONTRAC) | completed | Phase 3 | 160 | Traws Pharma, Inc.INDUSTRY | 5 | Aug 4, 2016 | clinicaltrials |
| NCT01911416 | A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer | withdrawn | N/A | 0 | University of UtahOTHER | 1 | Jun 9, 2016 | clinicaltrials |
| NCT02575508 | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | May 20, 2016 | clinicaltrials |
| NCT01962909 | Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer | terminated | Early Phase 1 | 3 | University of VirginiaOTHER | 1 | Mar 18, 2016 | clinicaltrials |
| NCT01274455 | Gene Therapy of Pancreatic Ductal Adenocarcinoma(TherGAP) | completed | Phase 1 | 22 | University Hospital, ToulouseOTHER | 1 | Mar 14, 2016 | clinicaltrials |
| NCT02707315 | A Study of Pre-Operative Cyberknife in Patients With Potentially Resectable Pancreas Cancer | unknown | Early Phase 1 | 15 | The Cooper Health SystemOTHER | 1 | Mar 14, 2016 | clinicaltrials |
| NCT01658943 | Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy(S1115) | completed | Phase 2 | 137 | National Cancer Institute (NCI)NIH | 1 | Mar 9, 2016 | clinicaltrials |
| NCT00375310 | Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer | completed | Phase 1 | 27 | Indiana UniversityOTHER | 1 | Feb 29, 2016 | clinicaltrials |
| NCT00574977 | Safety Study of Modified Vaccinia Virus to Cancer | completed | Phase 1 | 26 | David BartlettOTHER | 1 | Dec 28, 2015 | clinicaltrials |
| NCT02133079 | Immunotherapy of Tumor With Autologous Tumor Derived Heat Shock Protein gp96 | unknown | Phase 1 / Phase 2 | 20 | Cure&Sure Biotech Co., LTDINDUSTRY | 1 | Dec 11, 2015 | clinicaltrials |
| NCT01674556 | Ultrasound-assisted Treatment of Inoperable Pancreatic Cancer | completed | Phase 1 | 25 | Haukeland University HospitalOTHER | 1 | Sep 24, 2015 | clinicaltrials |
| NCT00598091 | A Phase I/Expansion Study of Dasatinib(Gem/Dsat) | terminated | Phase 1 | 30 | Duke UniversityOTHER | 1 | Sep 7, 2015 | clinicaltrials |
| NCT01419002 | Study to Evaluate if Neoadjuvant Radiotherapy Improves Recurrence Free Survival in Pancreatic Head Cancer(Net-Pac) | terminated | Phase 3 | 5 | CHIR-NetNETWORK | 1 | Jul 29, 2015 | clinicaltrials |
| NCT01050283 | A Study to Evaluate [18F]-FDG PET (Fluorodeoxyglucose-positron) in Patients With Pancreatic Cancer (MK-0000-144) | terminated | Phase 1 | 15 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 27, 2015 | clinicaltrials |
| NCT01879878 | Pilot Study Evaluating Broccoli Sprouts in Advanced Pancreatic Cancer [POUDER Trial](POUDER) | unknown | N/A | 40 | Heidelberg UniversityOTHER | 1 | May 28, 2015 | clinicaltrials |
| NCT00474812 | Dasatinib in Treating Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | May 5, 2015 | clinicaltrials |
| NCT00253526 | Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Apr 28, 2015 | clinicaltrials |
| NCT00588367 | CT Pancreas Perfusion | completed | — | 30 | Mayo ClinicOTHER | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00998322 | A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma | completed | Phase 2 | 34 | Oncolytics BiotechINDUSTRY | 1 | Apr 10, 2015 | clinicaltrials |
| NCT01834170 | EUS-guided Intratumoral Gemcitabine in Locally Advanced Unresectable Pancreatic Cancer | completed | Phase 1 | 12 | University of TehranOTHER | 1 | Dec 2, 2014 | clinicaltrials |
| NCT01232829 | Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Nov 26, 2014 | clinicaltrials |
| NCT00577889 | Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Jul 25, 2014 | clinicaltrials |
| NCT01227018 | PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer | terminated | Phase 2 | 15 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jul 23, 2014 | clinicaltrials |
| NCT01741597 | Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | May 30, 2014 | clinicaltrials |
| NCT00331682 | Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00091026 | Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer | completed | Phase 2 | 143 | National Cancer Institute (NCI)NIH | 1 | May 15, 2014 | clinicaltrials |
| NCT01124786 | A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP) | completed | Phase 2 | 367 | Clovis Oncology, Inc.INDUSTRY | 15 | Apr 17, 2014 | clinicaltrials |
| NCT00203892 | Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma | completed | Phase 1 / Phase 2 | 23 | University of ChicagoOTHER | 1 | Apr 16, 2014 | clinicaltrials |
| NCT01233505 | Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors | terminated | Phase 1 | 16 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Sep 13, 2017source: clinicaltrials